Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
The purpose of this phase I study is to evaluate the efficacy of modified FOLFIRINOX followed by stereotactic body radiotherapy (SBRT) in patients with borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC). The primary hypothesis will be to determine if modified FOLFIRINOX followed by SBRT improves progression free survival (PFS) compared to historical controls treated with gemcitabine-based chemotherapy with or without standard fractionated radiation.
Study ID: 2000024671
Trial Phase: Phase II
Trial Sponsor: Yale University
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Stereotactic body radiotherapy (SBRT), Irinotecan, Leucovorin, FOLFIRINOX